EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY-NC-ND 4.0

Efficacy of Treatments for T3bN0M0 Prostate Cancer Patients: A Systematic Review and Meta‐Analysis

Casper Reijnen iD, Wilma D Heemsbergen, Kimberley E Wever, Aishly Panneflek, Floris J Pos, J P Michiel Sedelaar, Uulke A van der Heide, Luca Incrocci, Robert Jan Smeenk

The Prostate · 2025

DOI: 10.1002/pros.70024 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift The Prostate, 2025. Verfasst von Casper Reijnen und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Radiation Oncology, Radboud University Medical Center, Nijmegen, The Netherlands. Hauptthemen laut MEDLINE: Prostatic Neoplasms. Die Arbeit nennt 54 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0). Gefördert von: The authors received no specific funding for this work..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Patients with prostate cancer (PC) invading into the seminal vesicles (SV) constitute a specific subgroup of high‐risk patients (staged as T3b) with a particularly high risk of disease recurrence, even when lymph node or distant metastases are absent (N0M0). The aim of the current systematic review and meta‐analysis was to investigate efficacy of available treatments for men with PC invading the SV without metastasis.

Methods

A systematic review was performed according to the Cochrane guidance and reported according to the guidelines for the Preferred Reporting Items for Systematic Reviews and Meta‐analyses. The review protocol was registered prospectively in the PROSPERO database. Studies identified in MEDLINE, EMBASE, and trial registries were selected by two independent reviewers. Treatment modalities included radical prostatectomy with pelvic lymphadenectomy; external beam radiotherapy (EBRT), high‐dose rate or low‐dose rate brachytherapy, androgen deprivation therapy (ADT), or a combination of treatments. Primary outcome measure was 5‐year biochemical recurrence free survival (BRFS).

Results

Twenty‐five studies, comprising 2 881 patients, were included. For EBRT and ADT pooled estimated 5‐year BRFS was 68%, varying from 56% in studies on low‐dose radiotherapy (< 74 Gray [Gy]), up to 78% in studies on high‐dose radiotherapy (≥ 74 Gy). For EBRT with brachytherapy and ADT pooled estimated 5‐year BRFS was 83%. For radical prostatectomy pooled estimated 5‐year BRFS was 32%. When combining surgery with adjuvant treatment (EBRT or ADT) pooled estimated 5‐year BRFS was 54% and 63%, respectively.

Conclusions

These results indicate a role for high‐dose radiotherapy (≥ 74 Gy) and long‐term ADT in T3bN0 PC rather than primary surgical treatment. In addition to dose‐escalated radiotherapy to the entire prostate gland (≥ 74 Gy), selected patients should be offered focal dose‐escalation to the tumor, by high‐dose rate brachytherapy. If proven safe for this patient group, focal dose‐escalation could also be offered with EBRT.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic NeoplasmsHumansMaleProstatectomyTreatment OutcomeNeoplasm StagingBrachytherapyAndrogen AntagonistsSeminal VesiclesLymph Node ExcisionCombined Modality TherapyNeoplasm Recurrence, Local

Stichwörter der Autor:innen

prostate cancerradiotherapyseminal vesiclessurgerysystematic reviewtherapy

Substanzen

Androgen Antagonists

Autor:innen und Institutionen

  • Department of Radiation Oncology, Radboud University Medical Center, Nijmegen, The Netherlands.
  • Department of Radiation Oncology, Erasmus MC Cancer Institute, Rotterdam, The Netherlands.
  • Department of Anaesthesiology, Pain and Palliative Medicine, Radboud University medical center, Nijmegen, The Netherlands.
  • Department of Biology, Radboud University, Nijmegen, The Netherlands.
  • Department of Radiation Oncology, The Netherlands Cancer Institute, Amsterdam, The Netherlands.
  • Department of Urology, Radboud University Medical Center, Nijmegen, The Netherlands.

ORCID-Profile: Casper Reijnen

Förderung

  • The authors received no specific funding for this work.

Zitieren

APA

Reijnen, C., Heemsbergen, W. D., Wever, K. E., Panneflek, A., Pos, F. J., Michiel Sedelaar, J. P., van der Heide, U. A., Incrocci, L., & Jan Smeenk, R. (2025). Efficacy of Treatments for T3bN0M0 Prostate Cancer Patients: A Systematic Review and Meta‐Analysis. The Prostate. https://doi.org/10.1002/pros.70024

Vancouver

Reijnen C, Heemsbergen WD, Wever KE, Panneflek A, Pos FJ, Michiel Sedelaar JP, et al. Efficacy of Treatments for T3bN0M0 Prostate Cancer Patients: A Systematic Review and Meta‐Analysis. The Prostate. 2025. doi:10.1002/pros.70024

BibTeX
@article{Reijnen2025,
  author = {Reijnen, Casper and Heemsbergen, Wilma D and Wever, Kimberley E and Panneflek, Aishly and Pos, Floris J and Michiel Sedelaar, J P and van der Heide, Uulke A and Incrocci, Luca and Jan Smeenk, Robert},
  title = {Efficacy of Treatments for T3bN0M0 Prostate Cancer Patients: A Systematic Review and Meta‐Analysis},
  journal = {The Prostate},
  year = {2025},
  doi = {10.1002/pros.70024}
}
Kostenlos starten →